Respiratory

Patients with COPD are typically characterized by lower physical activity (PA); lower PA levels are associated with both decreased lung function and accelerated deterioration of lung function.

June 7, 2024 is the target PDUFA date for the additional indication of GSK's respiratory syncytial virus vaccine Arexvy.

In response to a surge in cases of COVID-19, flu, and RSV, hospitals are reinstating mask guidelines to avoid adverse capacity outcomes and staffing shortages seen in prior years.

The vaccine, called mRNA-1345, demonstrated an efficacy of 83.7% against RSV-associated lower respiratory tract disease with at least 2 signs or symptoms and 82.4% against the disease with at least 3 signs or symptoms.

Higher concentrations of omega-3 fatty acids were associated with the ability to exchange carbon dioxide more efficiently and longer transplant-free survival.

Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.

A new report from the CDC demonstrated a decrease in cigarette smoking across all race and ethnic groups from 2016 to 2022, illustrating a promising trend with potential public health benefits.

In January 2024, Sanofi and AstraZenenca will release 230,000 additional doses of nirsevimab-alip, heeding guidance from the CDC to leverage all tools to increase immunizations against RSV.

Lupin gained FDA approval for varenicline tablets (0.5 mg and 1 mg) and launched its already-approved Turqoz (norgestrel and ethinyl estradiol) tablets USP, 0.3 mg/0.03 mg earlier this month.

Immunizations against influenza, COVID-19, and RSV are lower than they were this time last year, and hospitalizations have increased across all age groups.

A phase 4 study demonstrated that biologic therapies can control severe asthma while simultaneously helping patients minimize or eliminate harms associated with inhaled corticosteroids.

The NOTUS trial was shown to have successfully achieved its primary endpoint, demonstrating the notable efficacy of dupilumab in reducing exacerbations by 34% versus placebo in individuals with moderate-to-severe COPD showing evidence of type 2 inflammation.

The federal agencies said that they will continue to work closely with manufacturers to maintain the availability of the vaccines through the end of 2023 and early 2024 to meet the demand during the RSV season.

Maintaining a healthy diet before pregnancy was associated with a 10% reduced risk of children developing 'transient early' and 'persistent' wheeze patterns.

The capsule was developed by the pharmaceutical company Lupin and is a generic equivalent to Boehringer Ingelheim’s Spiriva HandiHaler.

A survey found that the proportion of primary care physicians who were unfamiliar with biologics and their eligibility criteria did not vary based on the number of asthma patients seen each month.

Understanding critical risk factors associated with the use of electronic nicotine delivery systems (ENDS) may help mitigate the harm dealt to youths by such devices.

Adverse effects of oral and inhaled corticosteroid use may impact quality of life for people with asthma.

Future disease-modifying interventions for COPD may greatly affect quality of life and survival.

Recognizing the challenges and needs associated with combating and preventing RSV may help reduce health care and patient burdens.

Stephen L. Foster, PharmD, FAPhA, FNAP, discussed the new vaccine and RSV prevalence at the National Community Pharmacists Association 2023 Convention and Expo.

Maternal immunization can prevent RSV in infants.

While baseline respiratory symptoms may increase the future risk of VTE in women, the study results did not find the same association in men.